Defects of the SCN5A gene encoding the cardiac sodium channel ␣-subunit are associated with both the long QT-3 (LQT-3) subtype of long-QT syndrome and Brugada syndrome (BrS). One previously described SCN5A mutation (1795insD) in the C terminus results in a clinical phenotype combining QT prolongation and ST segment elevation, indicating a close interrelationship between the two disorders. Here we provide additional evidence that these two disorders are closely related. We report the analysis of two novel mutations on the same codon, Y1795C (LQT-3) and Y1795H (BrS), expressed in HEK 293 cells and characterized using whole-cell patch clamp procedures. We find marked and opposing effects on channel gating consistent with activity associated with the cellular basis of each clinical disorder. Y1795H speeds and Y1795C slows the onset of inactivation. The Y1795H, but not the Y1795C, mutation causes a marked negative shift in the voltage dependence of inactivation, and neither mutation affects the kinetics of the recovery from inactivation. Interestingly, both mutations increase the expression of sustained Na ؉ channel activity compared with wild type (WT) channels, although this effect is most pronounced for the Y1795C mutation, and both mutations promote entrance into an intermediate or a slowly developing inactivated state. These data confirm the key role of the C-terminal tail of the cardiac Na ؉ channel in the control of channel gating, illustrate how subtle changes in channel biophysics can have significant and distinct effects in human disease, and, additionally, provide further evidence of the close interrelationship between BrS and LQT-3 at the molecular level.Mutations of SCN5A, the gene coding for the ␣-subunit of the cardiac sodium channel, have been linked to the following four human syndromes: congenital long QT syndrome type 3 (LQT-3), 1 Brugada syndrome (BrS), different types of conduction block (2), and sudden infant death syndrome (3-7). Despite this classification based on clinical characteristics such as ECG findings, age of first presentation, triggers of events, and others, significant clinical and pathophysiological overlap between these different disorders have been noted recently. This observation has led to the proposition that these syndromes are in fact only different appearances of a "unique" SCN5A disease. The most significant overlap exists between LQT-3 and the BrS (8). The most frequent presentation in both disorders is a history of syncope or cardiac arrests with a very high lethality, occurring mainly during rest or sleep and with a poor response to anti-adrenergic treatment such as  receptor blockade (9 -12). However, the typical electrocardiographic manifestations of long-QT syndrome (QT interval prolongation) and BrS (ST segment elevation in leads V1 through V3) may coexist in the same patients, which raises questions about the actual differences between LQT3 and BrS (8). Moreover, in some LQT-3 patients, exposure to the sodium channel blocker flecainide generates an ECG pattern th...